Affymetrix to acquire ParAllele in $120M deal

Affymetrix is buying South San Francisco-based ParAllele BioScience for $120 million in stock. The two have already been collaborating for the past two years. ParAllele can track thousands of drug reactions in a test tube with its assay technology while Affymetrix's technology opens up exploration of the genome.

"Together, Affymetrix and ParAllele have enabled new areas of science by offering products to explore the whole genome, as well as specific regions of interest," said Stephen P.A. Fodor, PhD, founder, chairman and CEO of Affymetrix. "The potential for ParAllele's technology goes far beyond genotyping. We will combine both companies' technologies to accelerate discovery and product development in a wide variety of areas, from basic research to the clinic."

- read this story from the AP on the buyout

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.